Preview

Пульмонология

Расширенный поиск

Интерстициальные заболевания легких: клинические рекомендации Британского торакального общества совместно с Торакальным обществом Австралии и Новой Зеландии и Ирландским торакальным обществом. Часть 1

https://doi.org/10.18093/0869-0189-2009-4-11-57

Полный текст:

Об авторах

А.У. Веллс

Россия


Н. Хирани

Россия


Список литературы

1. Cushley M.J., Davison A.G., du Bois R.M. et al. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54: S1-S30.

2. American Thoracic Society / European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277-304.

3. Katzenstein A.L., Fiorelli R.F. Nonspecific interstitial pneumonia / fibrosis. Histologic features and clinical significance. Am. J. Surg. Pathol. 1994; 18: 136-147.

4. Nicholson A.G., Colby T.V., du Bois R.M. et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 2000; 162: 2213-2217.

5. Flaherty K.R., Thwaite E.L., Kazerooni E.A. et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.

6. Flaherty K.R., King T.E. Jr., Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904-910.

7. Latsi P.I., du Bois R.M., Nicholson A.G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168: 531-537.

8. Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-1047.

9. Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-2242.

10. Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125-133.

11. Harbour R., Miller J. A new system for grading recommendations in evidence based guidelines. Br. Med. J. 2001; 323: 334-336.

12. Guyatt G., Vist G., Falck-Ytter Y. et al. An emerging consensus on grading recommendations? ACP J. Club 2006; 144: A8-A9.

13. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157: 199-203.

14. Cottin V., Donsbeck A.V., Revel D. et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am. J. Respir. Crit. Care Med. 1998; 158: 1286-1293.

15. Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1999; 160: 899-905.

16. Nagai S., Kitaichi M., Itoh H. et al. Idiopathic nonspecific interstitial pneumonia / fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur. Respir. J. 1998; 12: 1010-1019.

17. Schwartz D.A., Van Fossen D.S., Davis C.S. et al. Determinants of progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1994; 149: 444-449.

18. Travis W.D., Matsui K., Moss J. et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am. J. Surg. Pathol. 2000; 24: 19-33. 19. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161: 646-664.

19. Wells A.U., Hansell D.M., Nicholson A.G. What is this thing called CFA? Thorax 2007; 62: 3-4.

20. Nicholson A.G., Addis B.J., Bharucha H. et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500-505.

21. Hunninghake G.W., Zimmerman M.B., Schwartz D.A. et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 193-196.

22. Raghu G., Mageto Y.N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest 1999; 116: 1168-1174.

23. Wells A.U. Histopathologic diagnosis in diffuse lung disease: an ailing gold standard. Am. J. Respir. Crit. Care Med. 2004; 170: 828-829.

24. Wells A.U., Nicholson A.G., Hansell D.M. Challenges in pulmonary fibrosis 4: Smokinginduced diffuse interstitial lung diseases. Thorax 2007; 62: 904-910.

25. Vourlekis J.S., Schwarz M.I., Cool C.D. et al. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am. J. Med. 2002; 112: 490-493.

26. Churg A., Muller N.L., Flint J. et al. Chronic hypersensitivity pneumonitis. Am. J. Surg. Pathol. 2006; 30: 201-208.

27. Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165: 1581-1586.

28. Yoshinouchi T., Ohtsuki Y., Fujita J. et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol. Int. 2005; 26: 121-125.

29. Selman M., Pardo A., Barrera L. et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006; 173: 188-198.

30. Yang I.V., Burch L.H., Steele M.P. et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2007; 175: 45-54.

31. MacDonald S.L., Rubens M.B., Hansell D.M. et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221: 600-605.

32. Kim T.S., Lee K.S., Chung M.P. et al. Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. Am. J. Roentgenol. 1998; 171: 1645-1650.

33. Park J.S., Lee K.S., Kim J.S. et al. Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in seven patients. Radiology 1995; 195: 645-648.

34. Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990; 84: 365-369.

35. Doherty M.J., Pearson M.G., O'Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.

36. Collard H.R., King T.E. Jr., Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538-542.

37. Flaherty K.R., Mumford J.A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 543-548.

38. Jegal Y., Kim D.S., Shim T.S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005;171: 639-644.

39. King T.E. Jr., Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127: 171-177.

40. King T.E. Jr. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. 2000; 342: 974-975.

41. Kubo H., Nakayama K., Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.

42. Hunninghake G.W. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2285-2287.

43. Wells A.U. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur. Respir. J. 2006; 27: 664-666.

44. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134: 136-151.

45. Lok S.S. Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. Greater Manchester Lung Fibrosis Consortium. J. Heart Lung Transplant. 1999; 18: 884-890.

46. Hubbard R., Johnston I., Coultas D.B. et al. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51: 711-716.

47. Coultas D.B., Zumwalt R.E., Black W.C. et al. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967-972.

48. Thomeer M.J., Costabe U., Rizzato G. et al. Comparison of registries of interstitial lung diseases in three European countries. Eur. Respir. J. Suppl 2001; 32: 114s-118s.

49. von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir. Med. 2003; 97: 428-435.

50. Hansell A., Hollowell J., Nichols T. et al. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999; 54: 413-419.

51. Hubbard R., Johnston I., Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396-400.

52. Hubbard R., Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002; 41: 676-679.

53. Johnston I., Britton J., Kinnear W. et al. Rising mortality from cryptogenic fibrosing alveolitis. Br. Med. J. 1990; 301: 1017-1021.

54. Baumgartner K.B., Samet J.M., Coultas D.B. et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am. J. Epidemiol. 2000; 152: 307-315.

55. Iwai K., Mori T., Yamada N. et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994; 150: 670-675.

56. Palwatwichai A., Tiyanon W., Chaoprasong C. et al. Idiopathic pulmonary fibrosis, clinical features in Thai patients. J. Med. Assoc. Thai 2000; 83: 1248-1252.

57. Smith C., Feldman C., Levy H. et al. Cryptogenic fibrosing alveolitis. A study of an indigenous African population. Respiration 1990; 57: 364-371.

58. Mapel D.W., Hunt W.C., Utton R. et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998; 53: 469-476.

59. Hubbard R., Venn A., Lewis S. et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000; 161: 5-8.

60. Turner-Warwick M., Lebowitz M., Burrows B. et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.

61. Pietinalho A., Hiraga Y., Hosoda Y. et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 1995; 12: 61-67.

62. Rybicki B.A., Major M., Popovich J. Jr. et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am. J. Epidemiol. 1997; 145: 234-241.

63. Baughman R.P., Teirstein A.S., Judson M.A. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am. J. Respir. Crit. Care Med. 2001; 164: 1885-1889.

64. Byg K.E., Milman N., Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20: 46-52.

65. Kajdasz D.K., Judson M.A., Mohr L.C. Jr. et al. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am. J. Epidemiol. 1999; 150: 271-278.

66. Reich J.M. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39.

67. Gideon N.M., Mannino D.M. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am. J. Med. 1996; 100: 423-427.

68. Xaubet A., Ancochea J., Morell F. et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidos. Vasc. Diffuse Lung Dis. 2004; 21: 64-70.

69. Bourke S.J., Dalphin J.C., Boyd G. et al. Hypersensitivity pneumonitis: current concepts. Eur. Respir. J. 2001; 18: 81-92s.

70. Hendrick D.J., Faux J.A., Marshall R. Budgerigar-fancier's lung: the commonest variety of allergic alveolitis in Britain. Br. Med. J. 1978; 2: 81-84.

71. Vourlekis J.S., Schwarz M.I., Cherniack R.M. et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am. J. Med. 2004; 116: 662-668.

72. Tukiainen P., Taskinen E., Holsti P. et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-355.

73. Dawson J.K., Fewins H.E., Desmond J. et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-627.

74. Dawson J.K., Fewins H.E., Desmond J. et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2002; 61: 517-521.

75. Wells A.U., Cullinan P., Hansell D.M. et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1994; 149: 1583-1590.

76. Donaghy M., Rees A.J. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2: 1390-1393.

77. Baumgartner K.B., Samet J.M., Stidley C.A. et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997; 155: 242-248.

78. Kusaka H., Homma Y., Ogasawara H. et al. Five-year follow-up of Micropolyspora faeni antibody in smoking and nonsmoking farmers. Am. Rev. Respir. Dis. 1989; 140: 695-699.

79. Valeyre D., Soler P., Clerici C. et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 1988; 43: 516-524.

80. Brennan N.J., Crean P., Long J.P. et al. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984; 39: 14-18.

81. McGrath D.S., Daniil Z., Foley P. et al. Epidemiology of familial sarcoidosis in the UK. Thorax 2000; 55: 751-754.

82. Schurmann M., Lympany P.A., Reichel P. et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am. J. Respir. Crit. Care Med. 2000; 162: 861-864.

83. Barzo P. Familial idiopathic fibrosing alveolitis. Eur. J. Respir. Dis. 1985; 66: 350-352.

84. Cooper J.A. Jr., White D.A., Matthay R.A. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 488-505.

85. Cooper J.A. Jr., White D.A., Matthay R.A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 321-340.

86. Johnston I.D., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52: 38-44.

87. Kanematsu T., Kitaichi M., Nishimura K. et al. Clubbing of the fingers and smoothmuscle proliferation in fibrotic changes in the lung in patients with idiopathic pulmonary fibrosis. Chest 1994; 105: 339-342.

88. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.

89. Coutts I.I., Gilson J.C., Kerr I.H. et al. Significance of finger clubbing in asbestosis. Thorax 1987; 42: 117-119.

90. Sansores R., Salas J., Chapela R. et al. Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role. Arch. Intern. Med. 1990; 150: 1849-1851.

91. Grathwohl K.W., Thompson J.W., Riordan K.K. et al. Digital clubbing associated with polymyositis and interstitial lung disease. Chest 1995; 108: 1751-1752.

92. Epler G.R., Carrington C.B., Gaensler E.A. Crackles (rales) in the interstitial pulmonary diseases. Chest 1978; 73: 333-339.

93. Harrison N.K., Glanville A.R., Strickland B. et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir. Med. 1989; 83: 403-414.

94. Baughman R.P., Shipley R.T., Loudon R.G. et al. Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis. Chest 1991; 100: 96-101.

95. Earis J.E., Marsh K., Pearson M.G. et al. The inspiratory ''squawk'' in extrinsic allergic alveolitis and other pulmonary fibroses. Thorax 1982; 37: 923-926.

96. Panos R.J., Mortenson R.L., Niccoli S.A. et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 1990; 88: 396-404.

97. Sharma O.P., Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988; 94: 343-346.

98. Harrison B.D., Shaylor J.M., Stokes T.C. et al. Airflow limitation in sarcoidosis-a study of pulmonary function in 107 patients with newly diagnosed disease. Respir. Med. 1991; 85: 59-64.

99. Crausman R.S., Jennings C.A., Tuder R.M. et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am. J. Respir. Crit. Care Med. 1996; 153: 426-435.

100. Delobbe A., Durieu J., Duhamel A. et al. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur. Respir. J. 1996; 9: 2002-2006.

101. Kitaichi M., Nishimura K., Itoh H. et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med. 1995; 151: 527-533.

102. Taylor J.R., Ryu J., Colby T.V. et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N. Engl. J. Med. 1990; 323: 1254-1260.

103. Hanley M.E, King T.E. Jr., Schwarz M.I. et al. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am. Rev. Respir. Dis. 1991; 144: 1102-1106.

104. Schwartz D.A., Merchant R.K., Helmers R.A. et al. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1991; 144: 504-506.

105. Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167: 962-969.

106. Schwartz D.A., Helmers R.A., Galvin J.R. et al. Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1994; 149: 450-454.

107. Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063-1072.

108. Mogulkoc N., Brutsche M.H., Bishop P.W. et al. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am. J. Respir. Crit. Care Med. 2001; 164: 103-108.

109. Egan J.J., Martinez F.J., Wells A.U. et al. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60: 270-273.

110. Watters L.C., King T.E., Schwarz M.I. et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1986; 133: 97-103.

111. King T.E. Jr, Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171-1181.

112. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26: 948-68.

113. Hanson D., Winterbauer R.H., Kirtland S.H. et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108: 305-310.

114. Neville E., Walker A.N., James D.G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Quart. J. Med. 1983; 52: 525-533.

115. Sharma O.P. Pulmonary sarcoidosis and corticosteroids. Am. Rev. Respir. Dis. 1993; 147: 1598-1600.

116. Lynch J.P. III, Kazerooni E.A., Gay S.E. Pulmonary sarcoidosis. Clin. Chest Med. 1997; 18: 755-785.

117. Gibson G.J., Prescott R.J., Muers M.F. et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.

118. Lin Y.H., Haslam P.L., Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40: 501-507.

119. Muller N.L., Mawson J.B., Mathieson J.R. et al. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989; 171: 613-618.

120. Muers M.F., Middleton W.G., Gibson G.J. et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidos. Vasc. Diffuse Lung Dis. 1997; 14: 46-56.

121. Hansell D.M., Milne D.G., Wilsher M.L. et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998; 209: 697-704.

122. Drent M., De V.J., Lenters M. et al. Sarcoidosis: assessment of disease severity using HRCT. Eur. Radiol. 2003; 13: 2462-2471.

123. Alhamad E.H., Lynch J.P. III, Martinez F.J. Pulmonary function tests in interstitial lung disease: what role do they have? Clin. Chest Med. 2001; 22: 715-750, ix.

124. Lieberman J., Schleissner L.A., Nosal A. et al. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 1983; 84: 522-528.

125. Shorr A.F., Davies D.B., Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-928.

126. Goldstein D.S., Williams M.H. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax 1986; 41: 473-474.

127. Johns C.J., Schonfeld S.A., Scott P.P. et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann. N. Y. Acad. Sci. 1986; 465: 702-712.

128. Odlum C.M., Fitzgerald M.X. Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis. Sarcoidosis 1986; 3: 40-46.

129. Judson M.A., Baughman R.P., Thompson B.W. et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidos. Vasc. Diffuse Lung Dis. 2003; 20: 204-211.

130. Keogh B.A., Crystal RG. Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 1980; 78: 856-865.

131. Keogh B.A., Lakatos E., Price D. et al. Importance of the lower respiratory tract in oxygen transfer. Exercise testing in patients with interstitial and destructive lung disease. Am. Rev. Respir. Dis. 1984; 129: S76-S80.

132. Miller A., Brown L.K., Sloane M.F. et al. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995; 107: 323-329.

133. Marciniuk D.D., Gallagher C.G. Clinical exercise testing in interstitial lung disease. Clin. Chest Med. 1994; 15: 287-303.

134. Fulmer J.D., Roberts W.C., von Gal E.R. et al. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J. Clin. Invest. 1979; 63: 665-676.

135. Wells A.U., King A.D., Rubens M.B. et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am. J. Respir. Crit. Care Med. 1997; 155: 1367-1375.

136. Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthr. and Rheum. 1997; 40: 1229-1236.

137. Agusti C., Xaubet A., Agusti A.G. et al. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur. Respir. J. 1994; 7: 643-50.

138. Risk C., Epler G.R., Gaensler E.A. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest 1984; 85: 69-74.

139. Flaherty K.R., Andrei A.C., Murray S. et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 2006; 174: 803-809.

140. Hallstrand T.S., Boitano L.J., Johnson W.C. et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. 2005; 25: 96-103.

141. Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 1084-1090.

142. Lettieri C.J., Nathan S.D., Browning RF. et al. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir. Med. 2006; 100: 1734-1741.

143. Eaton T., Young P., Milne D. et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 1150-1157.

144. Kawut S.M., O'Shea M.K., Bartels M.N. et al. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir. Med. 2005; 99: 1431-1439.

145. Moloney E.D., Clayton N., Mukherjee D.K. et al. The shuttle walk exercise test in idiopathic pulmonary fibrosis. Respir. Med. 2003; 97: 682-687.

146. Epler G.R., McLoud T.C., Gaensler E.A. et al. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N. Engl. J. Med. 1978; 298: 934-939.

147. Gaensler E.A., Carrington C.B. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann. Thorac. Surg. 1980; 30: 411-426.

148. Mathieson J.R., Mayo J.R., Staples C.A. et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989; 171: 111-116.

149. McLoud T.C., Carrington C.B., Gaensler E.A. Diffuse infiltrative lung disease: a new scheme for description. Radiology 1983; 149: 353-363.

150. Schaefer-Prokop C., Uffmann M., Eisenhuber E. et al. Digital radiography of the chest: detector techniques and performance parameters. J. Thorac. Imag. 2003; 18: 124-137.

151. Mayo J.R., Webb W.R., Gould R. et al. High-resolution CT of the lungs: an optimal approach. Radiology 1987; 163: 507-510.

152. Johkoh T., Muller N.L., Nakamura H. Multidetector spiral high-resolution computed tomography of the lungs: distribution of findings on coronal image reconstructions.J. Thorac. Imag. 2002; 17: 291-305.

153. Remy-Jardin M., Campistron P., Amara A. et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J. Comput. Assist. Tomogr. 2003; 27: 266-273.

154. Mayo J.R., Aldrich J., Muller N.L. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 2003; 228: 15-21.

155. Muller N.L., Kullnig P., Miller R.R. The CT findings of pulmonary sarcoidosis: analysis of 25 patients. Am. J. Roentgenol. 1989; 152: 1179-1182.

156. Padley S.P., Adler B., Muller N.L. High-resolution computed tomography of the chest: current indications. J. Thorac. Imag. 1993; 8: 189-199.

157. Padley S.P., Hansell D.M., Flower CD. et al. Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin. Radiol. 1991; 44: 222-226.

158. Lynch D.A., Rose C.S., Way D. et al. Hypersensitivity pneumonitis: sensitivity of highresolution CT in a population-based study. A.J.R. Am. J. Roentgenol. 1992; 159: 469-472.

159. Orens J.B., Kazerooni E.A., Martinez F.J. et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest 1995; 108: 109-115.

160. Dalal P.U., Hansell D.M. High-resolution computed tomography of the lungs: the borderlands of normality. Eur. Radiol. 2006; 16: 771-780.

161. Remy-Jardin M., Remy J., Boulenguez C. et al. Morphologic effects of cigarette smoking on airways and pulmonary parenchyma in healthy adult volunteers: CT evaluation and correlation with pulmonary function tests. Radiology 1993; 186: 107-115.

162. Remy-Jardin M., Edme J.L., Boulenguez C. et al. Longitudinal follow-up study of smoker's lung with thin-section CT in correlation with pulmonary function tests. Radiology 2002; 222: 261-270.

163. Grenier P., Chevret S., Beigelman C. et al. Chronic diffuse infiltrative lung disease: determination of the diagnostic value of clinical data, chest radiography, and CT and Bayesian analysis. Radiology 1994; 191: 383-390.

164. Hartman T.E., Swensen S.J., Hansell D.M. et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology 2000; 217: 701-705.

165. Aziz Z.A., Wells A.U., Hansell D.M. et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59: 506-511.

166. Wells A.U., Rubens M.B., du Bois R.M. et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am. J. Roentgenol. 1993; 161: 1159-1165.

167. Remy-Jardin M., Giraud F., Remy J. et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693-698.

168. Sheehan R.E., Wells A.U., Milne D.G. et al. Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. J. Comput. Assist. Tomogr. 2000; 24: 259-261.

169. Muller N.L., Miller R.R., Webb W.R. et al. Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986; 160: 585-588.

170. Dawson J.K., Fewins H.E., Desmond J. et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2002; 61: 517-521.

171. Harrison B.J. Influence of cigarette smoking on disease outcome in rheumatoid arthritis. Curr. Opin. Rheumatol. 2002; 14: 93-97.

172. Klareskog L., Stolt P., Lundberg K. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthr. and Rheum. 2006; 54: 38-46.

173. McDonagh J., Greaves M., Wright A.R. et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 1994; 33: 118-122.

174. Saag K.G., Kolluri S., Koehnke R.K. et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthr. and Rheum. 1996; 39: 1711-1719.

175. Stolt P., Bengtsson C., Nordmark B. et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 2003; 62: 835-841.

176. Hesselstrand R., Scheja A., Shen G.Q. et al. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534-540.

177. Douglas W.W., Tazelaar H.D., Hartman T.E. et al. Polymyositis-dermatomyositisassociated interstitial lung disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1182-1185.

178. Costabel U., Hunninghake G.W. ATS / ERS / WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 1999; 14: 735-737.

179. Gupta D., Chetty M., Kumar N. et al. Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidos. Vasc. Diffuse Lung Dis. 2003; 20: 40-45.

180. Morell F., Levy G., Orriols R. et al. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest 2002; 121: 1239-1244.

181. Newman L.S., Rose C.S., Maier L.A. Sarcoidosis. N. Engl. J. Med. 1997; 336: 1224-1234.

182. Leung A.N., Brauner M.W., Caillat-Vigneron N. et al. Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay. J. Comput. Assist. Tomogr. 1998; 22: 229-234.

183. Shorr A.F., Torrington K.G., Parker J.M. Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis. Respir. Med. 1997; 91: 399-401.

184. Takada K., Ina Y., Noda M. et al. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J. Clin. Epidemiol. 1993; 46: 359-366.

185. Marshall B.G., Shaw R.J. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax 1998; 53: 439-440.

186. Stokes G.S., Monaghan J.C., Schrader A.P. et al. Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity. Aust. N. Z. J. Med. 1999; 29: 315-318.

187. Tahmoush A.J., Amir M.S., Connor W.W. et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidos. Vasc. Diffuse Lung Dis. 2002; 19: 191-197.

188. Sharma O.P. Hypercalcemia in granulomatous disorders: a clinical review. Curr. Opin. Pulm. Med. 2000; 6: 442-447.

189. Larsen F., Pehrsson S.K., Hammar N. et al. ECG-abnormalities in Japanese and Swedish patients with sarcoidosis. A comparison. Sarcoidos. Vasc. Diffuse Lung Dis. 2001; 18: 284-288.

190. Burrell R., Rylander R. A critical review of the role of precipitins in hypersensitivity pneumonitis. Eur. J. Respir. Dis. 1981; 62: 332-343.

191. Marcer G., Simioni L., Saia B. et al. Study of immunological parameters in farmer's lung. Clin. Allergy 1983; 13: 443-449.

192. Husman K., Vohlonen I., Terho E.O. et al. Precipitins against microbes in mouldy hay in the sera of farmers with farmer's lung or chronic bronchitis and of healthy farmers. Eur. J. Respir. Dis. Suppl. 1987; 152: 122-127.

193. Fink J.N., Ortega H.G., Reynolds H.Y. et al. Needs and opportunities for research in hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2005; 171: 792-798.

194. Ohtani Y., Kojima K., Sumi Y. et al. Inhalation provocation tests in chronic bird fancier's lung. Chest 2000; 118: 1382-1389.

195. Ramirez-Venegas A., Sansores R.H., Perez-Padilla R. et al. Utility of a provocation test for diagnosis of chronic pigeon Breeder's disease. Am. J. Respir. Crit. Care Med. 1998; 158: 862-869.

196. Yoshida K., Ando M., Sakata T. et al. Environmental mycological studies on the causative agent of summer-type hypersensitivity pneumonitis. J. Allergy Clin. Immunol. 1988; 81: 475-483. 198. British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56 (suppl. 1): i1-i21.

197. Credle W.F. Jr., Smiddy J.F., Elliott R.C. Complications of fiberoptic bronchoscopy. Am. Rev. Respir. Dis. 1974; 109: 67-72.

198. Pue C.A., Pacht E.R. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995; 107: 430-432.

199. Zavala D.C. Diagnostic fiberoptic bronchoscopy: techniques and results of biopsy in 600 patients. Chest 1975; 68: 12-19.

200. Herf S.M., Suratt P.M., Arora N.S. Deaths and complications associated with transbronchial lung biopsy. Am. Rev. Respir. Dis. 1977; 115: 708-711.

201. Andersen H.A. Transbronchoscopic lung biopsy for diffuse pulmonary diseases. Results in 939 patients. Chest 1978; 73: 734-736.

202. Simpson F.G., Arnold A.G., Purvis A. et al. Postal survey of bronchoscopic practice by physicians in the United Kingdom. Thorax 1986; 41: 311-317.

203. Descombes E., Gardiol D., Leuenberger P. Transbronchial lung biopsy: an analysis of 530 cases with reference to the number of samples. Monaldi Arch. Chest Dis. 1997; 52: 324-329.

204. Mitchell D.M., Emerson C.J., Collins J.V. et al. Transbronchial lung biopsy with the fibreoptic bronchoscope: analysis of results in 433 patients. Br. J. Dis. Chest 1981; 75: 258-262.

205. Zavala D.C. Pulmonary hemorrhage in fiberoptic transbronchial biopsy. Chest 1976; 70: 584-588.

206. Papin T.A., Lynch III J.P., Weg J.G. Transbronchial biopsy in the thrombocytopenic patient. Chest 1985; 88: 549-552.

207. Herth F.J., Becker H.D., Ernst A. Aspirin does not increase bleeding complications after transbronchial biopsy. Chest 202; 122: 1461-1464.

208. Haponik E.F., Summer W.R., Terry P.B. et al. Clinical decision making with transbronchial lung biopsies. The value of nonspecific histologic examination. Am. Rev. Respir. Dis. 1982; 125: 524-529.

209. Haslam P.L., Baughman R.P. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur. Respir. J. 1999; 14: 245-248.

210. Anon. Technical recommendations and guidelines for bronchoalveolar lavage (VBAL). Report of the European Society of Pneumology Task Group. Eur. Respir. J. 1989; 2: 561-285.

211. Anon. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. The BAL Cooperative Group Steering Committee. Am. Rev. Respir. Dis. 1990; 141: S169-S202.

212. Garcia J.G., Wolven R.G., Garcia P.L. et al. Assessment of interlobar variation of bronchoalveolar lavage cellular differentials in interstitial lung diseases. Am. Rev. Respir. Dis. 1986; 133: 444-449.

213. Peterson M.W., Nugent K.M., Jolles H. et al. Uniformity of bronchoalveolar lavage in patients with pulmonary sarcoidosis. Am. Rev. Respir. Dis. 1988; 137: 79-84.

214. Frigieri L., Mormile F., Grillie N. et al. Bilateral bronchoalveolar lavage in progressive systemic sclerosis: interlobar variability, lymphocyte subpopulations and functional correlations. Respiration 1991; 58: 132-140.

215. Agusti C., Xaubet A., Luburich P. et al. Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis. Thorax 1996; 51: 841-845.

216. Baughman R.P. Use of bronchoscopy in the diagnosis of infection in the immunocompromised host. Thorax 1994; 49: 3-7.

217. Betsuyaku T., Munakata M., Yamaguchi E. et al. Establishing diagnosis of pulmonary malignant lymphoma by gene rearrangement analysis of lymphocytes in bronchoalveolar lavage fluid. Am. J. Respir. Crit. Care Med. 1994; 149: 526-529.

218. Martin R.J., Coalson J.J., Rogers R.M. et al. Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am. Rev. Respir. Dis. 1980; 121: 819-825.

219. Winterbauer R.H., Lammert J., Selland M. et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104: 352-361.

220. Kantrow S.P., Meyer K.C., Kidd P. et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur. Respir. J. 1997; 10: 2716-2721.

221. Costabel U., Guzman J. Bronchoalveolar lavage in interstitial lung disease. Curr. Opin. Pulm. Med. 2001; 7: 255-261.

222. Drent M., van Nierop M.A., Gerritsen F.A. et al. A computer program using BALF analysis results as a diagnostic tool in interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1996; 153: 736-741.

223. Drent M., Grutters J.C., Mulder P.G. et al. Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile? Sarcoidos. Vasc. Diffuse Lung Dis. 1997; 14: 31-38.

224. Drent M., Jacobs J.A., De V.J. et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur. Respir. J. 1999; 13: 1338-1344.

225. Ziegenhagen M.W., Rothe M.E., Schlaak M. et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur. Respir. J. 2003; 21: 407-413.

226. Park C.S., Chung S.W., Ki S.Y. et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic non-specific interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2000; 162: 1162-1168.

227. Veeraraghavan S., Latsi P.I., Wells AU. et al. BAL findings in idiopathic non-specific interstitial pneumonia and usual interstitial pneumonia. Eur. Respir. J. 2003; 22: 239-244.

228. Drent M., du Bois R.M., Poletti V. Recent advances in the diagnosis and management of nonspecific interstitial pneumonia. Curr. Opin. Pulm. Med. 2003; 9: 411-417.

229. Gabbay E., Tarala R., Will R. et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 1997; 156: 528-535.

230. Wallaert B., Hatron P.Y., Grosbois J.M. et al. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am. Rev. Respir. Dis. 1986; 133: 574-580.

231. Silver R.M., Miller K.S., Kinsella M.B. et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am. J. Med. 1990; 88: 470-476.

232. White B., Moore W.C., Wigley F.M. et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 2000; 132: 947-954.

233. Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am. J. Respir. Crit. Care Med. 1994; 150: 462-468.

234. Wells A.U., Hansell D.M., Haslam P.L. et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am. J. Respir. Crit. Care Med. 1998; 157: 1474-1482.

235. Fechner R.E. Greenberg S.D, Wilson R.K. et al. Evaluation of transbronchial biopsy of the lung. Am. J. Clin. Pathol. 1977; 68: 17-20.

236. Wall C.P., Gaensler E.A., Carrington C.B. et al. Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am. Rev. Respir. Dis. 1981; 123: 280-285.

237. Poletti V., Patelli M., Ferracini R. et al. Transbronchial lung biopsy in infiltrative lung disease. The importance of the pathologic approach. Sarcoidosis 1988; 5: 43-50.

238. Mitchell D.M., Mitchell D.N., Collins J.V. et al. Transbronchial lung biopsy through fibreoptic bronchoscope in diagnosis of sarcoidosis. Br. Med. J. 1980; 280: 679-681.

239. Puar H.S., Young Jr. R.C., Armstrong E.M. Bronchial and transbronchial lung biopsy without fluoroscopy in sarcoidosis. Chest 1985; 87: 303-306.

240. Glaspole I.N., Wells A.U., du Bois R.M. Lung biopsy in diffuse parenchymal lung disease. Monaldi Arch. Chest Dis. 2001; 56: 225-232.

241. Gilman M.J., Wang K.P. Transbronchial lung biopsy in sarcoidosis. An approach to determine the optimal number of biopsies. Am. Rev. Respir. Dis. 1980; 122: 721-724.

242. Curley F.J., Johal J.S., Burke M.E. et al. Transbronchial lung biopsy: can specimen quality be predicted at the time of biopsy? Chest 1998; 113: 1037-1041.

243. Bjermer L., Thunell M., Rosenhall L. et al. Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir. Med. 1991; 85: 229-234.

244. Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001; 120: 109-114.

245. Armstrong J.R., Radke J.R., Kvale P.A. et al. Endoscopic findings in sarcoidosis. Characteristics and correlations with radiographic staging and bronchial mucosal biopsy yield. Ann. Otol. St. Louis. 1981; 90: 339-343.

246. Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001; 120: 881-886.

247. Neuhaus S.J., Matar K.S. The efficacy of open lung biopsy. Aust. N. Z. J. Surg. 1997; 67: 181-184.

248. Qureshi R.A., Soorae A.A. Efficacy of thoracoscopic lung biopsy in interstitial lung diseases: comparison with open lung biopsy. J. Coll. Physicians Surg. Pak. 2003; 13: 600-603.

249. Ray J.F. III, Lawton B.R., Myers WO. et al. Open pulmonary biopsy. Nineteen-year experience with 416 consecutive operations. Chest 1976; 69: 43-47.

250. Shah S.S., Tsang V., Goldstraw P. Open lung biopsy: a safe, reliable and accurate method for diagnosis in diffuse lung disease. Respiration 1992; 59: 243-246.

251. Daniil Z., Gilchrist F.C., Marciniak S.J. et al. The effect of lung biopsy on lung function in diffuse lung disease. Eur. Respir. J. 2000; 16: 67-73.

252. Utz J.P., Ryu J.H., Douglas W.W. et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur. Respir. J. 2001; 17: 175-179.

253. Carrillo G., Estrada A., Pedroza J. et al. Preoperative risk factors associated with mortality in lung biopsy patients with interstitial lung disease. J. Invest. Surg. 2005; 18: 39-45.

254. Lettieri C.J., Veerappan G.R., Helman D.L. et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127: 1600-1605.

255. Kramer M.R., Berkman N., Mintz B. et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann. Thorac. Surg. 1998; 65: 198-202.

256. Qureshi R.A., Ahmed T.A., Grayson A.D. et al. Does lung biopsy help patients with interstitial lung disease? Eur. J. Cardiothorac. Surg. 2002; 21: 621-626.

257. Sedrakyan A., van der M.J., Lewsey J. et al. Variation in use of video assisted thoracic surgery in the United Kingdom. Br. Med. J. 2004; 329: 1011-1012.

258. Ayed A.K., Raghunathan R. Thoracoscopy versus open lung biopsy in the diagnosis of interstitial lung disease: a randomised controlled trial. J. Roy. Coll. Surg. Edinb. 2000; 45: 159-163.

259. Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647-1650.

260. Santambrogio L., Nosotti M., Bellaviti N. et al. Videothoracoscopy versus thoracotomy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann. Thorac. Surg. 1995; 59: 868-870.

261. Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax 1994; 49: 361-363.

262. Hazelrigg S.R., Nunchuck S.K., Landreneau R.J. et al. Cost analysis for thoracoscopy: thoracoscopic wedge resection. Ann. Thorac. Surg. 1993; 56: 633-635.

263. Molin L.J., Steinberg J.B., Lanza L.A. VATS increases costs in patients undergoing lung biopsy for interstitial lung disease. Ann. Thorac. Surg. 1994; 58: 1595-1698.

264. Sugi K., Kaneda Y., Nawata K. et al. Cost analysis for thoracoscopy: thoracoscopic wedge resection and lobectomy. Surg. Today 1998; 28: 41-45.

265. Kramer M.R., Berkman N., Mintz B. et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann. Thorac. Surg. 1998; 65: 198-202.

266. Newman S.L., Michel R.P., Wang N.S. Lingular lung biopsy: is it representative? Am. Rev. Respir. Dis. 1985;132: 1084-1086.

267. Chechani V., Landreneau R.J., Shaikh S.S. Open lung biopsy for diffuse infiltrative lung disease. Ann. Thorac. Surg. 1992; 54: 296-300.

268. Miller R.R., Nelems B., Muller N.L. et al. Lingular and right middle lobe biopsy in the assessment of diffuse lung disease. Ann. Thorac. Surg. 1987; 44: 269-273.

269. Temes R.T., Joste N.E., Allen N.L. et al. The lingula is an appropriate site for lung biopsy. Ann. Thorac. Surg. 2000; 69: 1016-1018.

270. Wetstein L. Sensitivity and specificity of lingular segmental biopsies of the lung. Chest 1986; 90: 383-386.

271. Katzenstein A.L., Zisman D.A., Litzky L.A. et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am. J. Surg. Pathol. 2002; 26: 1567-1577.

272. Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722-1727.

273. Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125: 522-526.

274. Yung R.C., Weinacker A.B., Steiger D.J. et al. Upper and middle lobe bronchoalveolar lavage to diagnose Pneumocystis carinii pneumonia. Am. Rev. Respir. Dis. 1993; 148: 1563-1566.

275. Taylor I.K., Coker R.J., Clarke J. et al. Pulmonary complications of HIV disease: 10 year retrospective evaluation of yields from bronchoalveolar lavage, 1983-1993. Thorax 1995; 50: 1240-1245.

276. Unger E.R., Budgeon L.R., Myerson D. et al. Viral diagnosis by in situ hybridization. Description of a rapid simplified colorimetric method. Am. J. Surg. Pathol. 1986; 10: 1-8.

277. Turner-Warwick M., Lebowitz M., Burrows B. et al. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496-499.

278. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999.

279. Arima K., Ando M., Ito K. et al. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch. Environ/ Hlth 1992; 47: 274-278.

280. Baldwin C.I., Todd A., Bourke S. et al. Pigeon fanciers' lung: effects of smoking on serum and salivary antibody responses to pigeon antigens. Clin. Exp. Immunol. 1998; 113: 166-172.

281. Dalphin J.C., Debieuvre D., Pernet D. et al. Prevalence and risk factors for chronic bronchitis and farmer's lung in French dairy farmers. Br. J. Industr. Med. 1993; 50: 941-944.

282. Depierre A., Dalphin J.C., Pernet D. et al. Epidemiological study of farmer's lung in five districts of the French Doubs province. Thorax 1988; 43: 429-435.

283. Douglas J.G., Middleton W.G., Gaddie J. et al. Sarcoidosis: a disorder commoner in non-smokers? Thorax 1986; 41: 787-791.

284. Harf R.A., Ethevenaux C., Gleize J. et al. Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. Ann. N. Y. Acad. Sci. 1986; 465: 625-631.

285. McSharry C., Banham S.W., Boyd G. Effect of cigarette smoking on the antibody response to inhaled antigens and the prevalence of extrinsic allergic alveolitis among pigeon breeders. Clin. Allergy 1985; 15: 487-494.

286. Ohtsuka Y., Munakata M., Tanimura K. et al. Smoking promotes insidious and chronic farmer's lung disease, and deteriorates the clinical outcome. Intern. Med. 1995; 34: 966-971.

287. Jastrzebski D., Gumola A., Gawlik R. et al. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57 (suppl. 4): 139-148.

288. Naji N.A., Connor M.C., Donnelly S.C. et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237-243.

289. Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary Rehabilitation: Joint ACCP / AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S-42S.

290. De Vries J., Kessels B.L., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2001; 17: 954-961.

291. Crockett A.J., Cranston J.M., Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database Syst. Rev. 2001: CD002883.

292. Clark M., Cooper B., Singh S. et al. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax 2001; 56: 482-486.

293. Polosa R., Simidchiev A., Walters E.H. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst. Rev. 2002: CD002872.

294. Doherty M.J., Mister R., Pearson M.G. et al. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000; 55: 1028-1032.

295. Hope-Gill B.D., Hilldrup S., Davies C. et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 995-1002.

296. Hansen-Flaschen J. Advanced lung disease. Palliation and terminal care. Clin. Chest Med. 1997; 18: 645-655.

297. Tobin R.W., Pope C.E., Pellegrini C.A. et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158: 1804-1808.

298. Raghu G., Freudenberger T.D., Yang S. et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 27: 136-142.

299. Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129: 794-800.

300. Franquet T., Gimenez A., Torrubia S. et al. Spontaneous pneumothorax and pneumomediastinum in IPF. Eur. Radiol. 2000; 10: 108-113.

301. Kumar P., Goldstraw P., Yamada K. et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J. Thorac. Cardiovasc. Surg. 2003; 125: 1321-1327.

302. Raghu G., Nyberg F., Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 2004; 91 (suppl. 2): S3-S10.

303. Carrington C.B., Gaensler E.A., Coutu R.E. et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 1978; 298: 801-809.

304. Scadding J.G. Chronic diffuse interstitial fibrosis of the lungs. Br. Med. J. 1960; 1: 443-450.

305. Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996; 110: 1058-1067.

306. Millar A. Anti-cytokine therapy in fibrosing alveolitis: where are we now? Respir. Res. 2000; 1: 3-5.

307. Nagai S., Kitaichi M., Hamada K. et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidos. Vasc. Diffuse Lung Dis. 1999; 16: 209-214.

308. Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000;161: 1172-1178.

309. Magro C.M., Allen J., Pope-Harman A. et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am. J. Clin. Pathol. 2003; 119: 556-567.

310. Lynch J.P. III, White E., Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med. 2001; 7: 298-308.

311. Richeldi L., Davies H.R., Ferrara G. et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003: CD002880.

312. Winterbauer R.H., Hammar S.P., Hallman K.O. et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone / azathioprine. Am. J. Med. 1978; 65: 661-672.

313. Raghu G., DePaso W.J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991; 144: 291-296.

314. Cantin A.M., Hubbard R.C., Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1989; 139: 370-372.

315. Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156: 1897-1901.

316. Clark J.G., Dedon T.F., Wayner E.A. et al. Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J. Clin. Invest. 1989; 83: 1505-1511.

317. Narayanan A.S., Whithey J., Souza A. et al. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992; 101: 1326-1331.

318. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-beta / SMAD signalling by the interferon-gamma / STAT pathway. Nature 1999; 397: 710-713.

319. Okada T., Sugie I., Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res. 1993;12: 87-91.

320. Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999; 341: 1264-1269.

321. Kalra S., Utz J.P., Ryu J.H. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin. Proc. 2003; 78: 1082-1087.

322. Antoniou K.M., Nicholson A.G., Dimadi M. et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 28: 496-504.

323. Ziesche R., Hofbauer E., Wittmann K. et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999; 341: 1264-1269.

324. Bajwa E.K., Ayas N.T., Schulzer M. et al. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005; 128: 203-206.

325. Honore I., Nunes H., Groussard O. et al. Acute respiratory failure after interferongamma therapy of end-stage pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 953-957.

326. Johnson M.A., Kwan S., Snell N.J. et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.

327. Zisman D.A., Lynch J.P. III, Toews G.B. et al. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117: 1619-1626.

328. Collard H.R., Ryu J.H., Douglas W.W. et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.

329. Baughman R.P., Lower E.E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-1094.

330. Dayton C.S., Schwartz D.A., Helmers R.A. et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993; 103: 69-73.

331. Kolb M., Kirschner J., Riedel W. et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur. Respir. J. 1998; 12: 1409-1414.

332. Lynch J.P. III, McCune W.J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am. J. Respir. Crit. Care Med. 1997; 155: 395-420.

333. Iyer S.N., Gurujeyalakshmi G., Giri S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999; 291: 367-373.

334. Iyer S.N., Wild J.S., Schiedt M.J. et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 1995; 125: 779-785.

335. Gahl W.A., Brantly M., Troendle J. et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 2002; 76: 234-242.

336. Raghu G., Johnson W.C., Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061-1069.

337. Nagai S., Hamada K., Shigematsu M. et al. Open-label compassionate use one year treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 2002; 41: 1118-1123.

338. Carpagnano G.E., Kharitonov S.A., Wells A.U. et al. Increased vitronectin and endothelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration 2003; 70: 154-160.

339. Giaid A., Michel R.P., Stewart D.J. et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554.

340. Hocher B., Schwarz A., Fagan K.A. et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 2000; 23: 19-26.

341. Mutsaers S.E., Marshall R.P., Goldsack N.R. et al. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. 1998; 11: 221-225.

342. Park S.H., Saleh D., Giaid A. et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 1997; 156: 600-608.

343. Shahar I., Fireman E., Topilsky M. et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999; 21: 759-775.

344. Miyazaki Y., Araki K., Vesin C. et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995; 96: 250-259.

345. Piguet P.F., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. 1994; 7: 515-518.

346. Thrall R.S., Vogel S.N., Evans R. et al. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 1997; 151: 1303-1310.

347. Freeburn R.W., Armstrong L., Millar A.B. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) inductions. Eur Cytokine Netw 2005; 16: 5-16.

348. Zhang Y., Lee T.C., Guillemin B. et al. Enhanced IL-1 beta and tumor necrosis factor alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J. Immunol. 1993; 150: 4188-4196.

349. Chambers R.C. Role of coagulation cascade proteases in lung repair and fibrosis. Eur. Respir. J. Suppl. 2003; 44: 33s-35s.

350. Hernandez-Rodriguez N.A., Cambrey A.D., Harrison N.K. et al. Role of thrombin in pulmonary fibrosis. Lancet 1995; 346: 1071-1073.

351. Imokawa S., Sato A., Hayakawa H. et al. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 1997; 156: 631-636.

352. Addrizzo-Harris D.J., Harkin T.J., Tchou-Wong K.M. et al. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. Lung 2002; 180: 61-72.

353. Entzian P., Schlaak M., Seitzer U. et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51.

354. Rennard S.I., Bitterman P.B., Ozaki T. et al. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach to the fibrotic disorders. Am. Rev. Respir. Dis. 1988; 137: 181-185.

355. Douglas W.W., Ryu J.H., Swensen S.J. et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am. J. Respir. Crit. Care Med. 1998; 158: 220-225.

356. Selman M., Carrillo G., Salas J. et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-512.

357. Fedullo A.J., Karlinsky J.B., Snider G.L. et al. Lung statics and connective tissues after penicillamine in bleomycin-treated hamsters. J. Appl. Physiol. 1980; 49: 1083-1090.

358. Geismar L.S., Hennessey S., Reiser K.M. et al. D-penicillamine prevents collagen accumulation in lungs of rats given bleomycin. Chest 1986; 89: 153S-154S.

359. Meier-Sydow J., Rust M., Kronenberger H. et al. [Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or d-penicillamine]. Prax. Klin. Pneumol. 1979; 33 (suppl. 1): 680-688.

360. Borel J.F. Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo. Pharmacol. Rev. 1990; 41: 259-371.

361. Eickelberg O., Pansky A., Koehler E. et al. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J. 2001; 15: 797-806.

362. Alton E.W., Johnson M., Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir. Med. 1989; 83: 277-279.


Для цитирования:


Веллс А., Хирани Н. Интерстициальные заболевания легких: клинические рекомендации Британского торакального общества совместно с Торакальным обществом Австралии и Новой Зеландии и Ирландским торакальным обществом. Часть 1 . Пульмонология. 2009;(4):11-57. https://doi.org/10.18093/0869-0189-2009-4-11-57

Просмотров: 5


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)